Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate

Annals of Neurology

Volumn 78, Issue 4, 2015, Pages 501-514

  Bartsch, Thorsten ^a   Rempe, Torge ^a   Wrede, Arne ^b   Leypoldt, Frank ^a   Brück, Wolfgang ^b   Adams, Ortwin ^c   Rohr, Axel ^a   Jansen, Olav ^a   Wüthrich, Christian ^d,e   Deuschl, Günther ^a   Koralnik, Igor J ^d,e  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c Department of Orthopedic Surgery   (Germany)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FUMADERM; VIRUS DNA; DERMATOLOGICAL AGENT; FUMARIC ACID DIMETHYL ESTER;

AGED; ARTICLE; BRAIN BIOPSY; BRAIN DYSFUNCTION; BRAIN STEM; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CEREBROSPINAL FLUID; DISEASE SEVERITY; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; JC VIRUS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RIGHT HEMISPHERE; SEIZURE; TREATMENT DURATION; CHEMICALLY INDUCED; DISEASE COURSE; FOLLOW UP; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;

AGED; DERMATOLOGIC AGENTS; DIMETHYL FUMARATE; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; PSORIASIS;

EID: 84942373937     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24471     Document Type: Article

References (57)

1. Longbrake EE, Cross AH,. Dimethyl fumarate associated lymphopenia in clinical practice. Mult Scler 2015; 21: 796-797.
2. Koralnik IJ,. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006; 60: 162-173.
3. Gheuens S, Wuthrich C, Koralnik IJ,. Progressive multifocal leukoencephalopathy: why gray and white matter. Annu Rev Pathol 2013; 8: 189-215.
4. Koralnik IJ, Boden D, Mai VX, et al., JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999; 52: 253-260.
5. Cinque P, Scarpellini P, Vago L, et al., Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 1997; 11: 1-17.
6. Antinori A, Cingolani A, Lorenzini P, et al., Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9 (suppl 1): 47-53.
7. Marzocchetti A, Di Giambenedetto S, Cingolani A, et al., Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005; 43: 4175-4177.
8. Kuhle J, Gosert R, Buhler R, et al., Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 2011; 77: 2010-2016.
9. Mazda ME, Brosch JR, Wiens AL, et al., A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing. Int J Neurosci 2013; 123: 353-357.
10. Vermersch P, Kappos L, Gold R, et al., Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011; 76: 1697-1704.
11. Berger JR, Aksamit AJ, Clifford DB, et al., PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80: 1430-1438.
12. Plavina T, Subramanyam M, Bloomgren G, et al., Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76: 802-812.
13. Warnke C, von Geldern G, Markwerth P, et al., Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76: 792-801.
14. Viscidi RP, Khanna N, Tan CS, et al., JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis 2011; 53: 711-715.
15. Molloy ES, Calabrese LH,. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012; 64: 3043-3051.
16. Wollebo HS, White MK, Gordon J, et al., Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol 2015; 77: 560-570.
17. Hoxtermann S, Nuchel C, Altmeyer P,. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology 1998; 196: 223-230.
18. Gheuens S, Bord E, Kesari S, et al., Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 2011; 85: 7256-7263.
19. Marzocchetti A, Tompkins T, Clifford DB, et al., Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009; 73: 1551-1558.
20. Du Pasquier RA, Kuroda MJ, Zheng Y, et al., A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004; 127 (pt 9): 1970-1978.
21. Treumer F, Zhu K, Glaser R, Mrowietz U,. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121: 1383-1388.
22. de Jong R, Bezemer AC, Zomerdijk TP, et al., Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26: 2067-2074.
23. Vandermeeren M, Janssens S, Wouters H, et al., Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells. J Invest Dermatol 2001; 116: 124-130.
24. Gergely P,. Drug-induced lymphopenia: focus on CD4+ and CD8+ cells. Drug Saf 1999; 21: 91-100.
25. Khatri B, Garland J, Berger J, et al., The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: a potential contributor to progressive multifocal leukoencephalopathy risk. Mult Scler Relat Disord 2015; 4: 377-379.
26. Ermis U, Weis J, Schulz JB,. PML in a patient treated with fumaric acid. N Engl J Med 2013; 368: 1657-1658.
27. van Oosten BW, Killestein J, Barkhof F, et al., PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013; 368: 1658-1659.
28. Rosenkranz T, Novas M, Terborg C,. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 2015; 372: 1476-1478.
29. Fox RJ, Miller DH, Phillips JT, et al., Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087-1097.
30. Gold R, Kappos L, Arnold DL, et al., Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098-1107.
31. Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, et al., Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2015; 2: e76.
32. Gheuens S, Pierone G, Peeters P, Koralnik IJ,. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 2010; 81: 247-254.
33. Naess H, Glad S, Storstein A, et al., Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. BMC Neurol 2010; 10: 32.
34. Ahmad DS, Esmadi M, Steinmann WC,. Idiopathic CD4 lymphocytopenia: spectrum of opportunistic infections, malignancies, and autoimmune diseases. Avicenna J Med 2013; 3: 37-47.
35. Regent A, Autran B, Carcelain G, et al., Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients. Medicine (Baltimore) 2014; 93: 61-72.
36. McGuire JL, Fridman V, Wuthrich C, et al., Progressive multifocal leukoencephalopathy associated with isolated CD8+ T-lymphocyte deficiency mimicking tumefactive MS. J Neurovirol 2011; 17: 500-503.
37. Du Pasquier RA, Schmitz JE, Jean-Jacques J, et al., Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J Virol 2004; 78: 10206-10210.
38. Lima MA, Marzocchetti A, Autissier P, et al., Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol 2007; 81: 3361-3368.
39. Lima MA, Drislane FW, Koralnik IJ,. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 2006; 66: 262-264.
40. Khoury MN, Alsop DC, Agnihotri SP, et al., Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy. Ann Neurol 2014; 75: 659-669.
41. Wuthrich C, Koralnik IJ,. Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 2012; 71: 54-65.
42. Berger JR, Levy RM, Flomenhoft D, Dobbs M,. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998; 44: 341-349.
43. Gheuens S, Ngo L, Wang X, et al., Metabolic profile of PML lesions in patients with and without IRIS: an observational study. Neurology 2012; 79: 1041-1048.
44. Yousry TA, Pelletier D, Cadavid D, et al., Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012; 72: 779-787.
45. Wattjes MP, Richert ND, Killestein J, et al., The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 2013; 19: 1826-1840.
46. Dahlhaus S, Hoepner R, Chan A, et al., Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 2013; 84: 1068-1074.
47. Schroder A, Lee DH, Hellwig K, et al., Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 2010; 67: 1391-1394.
48. Elphick GF, Querbes W, Jordan JA, et al., The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306: 1380-1383.
49. Verma S, Cikurel K, Koralnik IJ, et al., Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis 2007; 196: 709-711.
50. Cettomai D, McArthur JC,. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009; 66: 255-258.
51. Stoppe M, Thoma E, Liebert UG, et al., Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis. J Neurol 2014; 261: 1021-1024.
52. Hoepner R, Faissner S, Klasing A, et al., Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis. Neurol Neuroimmunol Neuroinflamm 2015; 2: e85.
53. Nieuwkamp DJ, Murk JL, van Oosten BW, et al., PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med 2015; 372: 1474-1476.
54. Brickelmaier M, Lugovskoy A, Kartikeyan R, et al., Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009; 53: 1840-1849.
55. Clifford DB, Nath A, Cinque P, et al., A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol 2013; 19: 351-358.
56. Koralnik IJ,. Finger pointing to JC virus: a tale of two indexes. Ann Neurol 2014; 76: 789-791.
57. Chen Y, Bord E, Tompkins T, et al., Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361: 1067-1074.